Thank you to all who have supported Chris and I in our efforts to raise money for Breast Cancer research through Fred Hutchinson Cancer Research Center’s, Climb to Fight Breast Cancer. To date we have raised nearly $27,000. We are still actively fundraising until our Climb of Denali June 12, 2012.
If you have not already supported us, please consider donating by clicking on the link on the side of our blog.
Thank you!
What Your Dollars Support
Scaling a mountain is a good metaphor for cancer research. In both cases the challenges are unknown until you are in the middle of it, and no one wants to turn back. At Fred Hutchinson Cancer Research Center we face the mountainous challenge of eliminating cancer as a cause of human suffering and death. Achieving such a lofty goal requires the determination and dedication of world-class researchers, the most advanced tools and a collaborative spirit.
By supporting the Climb to Fight Breast Cancer, you’ve become a part of this challenge. Your contributions — on or off the mountain — play a pivotal role in accelerating the Hutchinson Center’s efforts to detect, treat and prevent breast cancer, saving countless lives in the process. In this report, we highlight two recent developments in breast cancer research. One focuses on arming scientists with tools for accelerating the development of biomarkers that can improve cancer early detection, the other on understanding disease risk factors. Each represents a significant stride forward in our quest to overcome breast cancer and advance research into other cancers as well.
A roadmap for biomarker development
Dr. Amanda Paulovich, an investigator in the Clinical Research Division, and her colleagues have generated a roadmap that should help researchers more efficiently develop useful cancer biomarkers — molecules that can signal the presence of disease.
Despite significant investment in recent years to discover proteins that could be used as the basis for simple blood tests to detect cancer and monitor treatment, the Food and Drug Administration has approved very few such biomarkers. This is due in part to the fact that clinical tests for the proteins have to be developed from scratch, a process that is too expensive to be done for every potential biomarker that scientists identify in the lab.
To overcome this research bottleneck, Dr. Paulovich’s team took an existing, highly sensitive and targeted technology called selected reaction monitoring mass spectrometry, applied it in a new way, and combined it with other state-of-the-art techniques for analyzing proteins. They tested their approach using laboratory models of breast cancer and found their technology platform allowed them to reliably measure many proteins from a small drop of blood — far more than would have been possible using conventional approaches.
Dr. Paulovich hopes the findings will streamline the process of prioritizing and testing candidate biomarkers so that discoveries in the lab can be more quickly and successfully translated into clinical tools for the early detection and treatment of breast and other cancers. Ultimately, such tools bring the reality of a blood test for the early detection and diagnosis of various cancers a step closer.
Births raise risk of rare form of breast cancer
Recently, in one of the largest studies of its kind ever conducted, Dr. Amanda Phipps, a postdoctoral research associate in the Public Health Sciences Division, and colleagues studied the detailed health histories of 150,000 postmenopausal women. They found the more times a woman gives birth, the higher her risk of triple-negative breast cancer, a rare but aggressive subtype of the disease. The findings surprised Dr. Phipps’s team since researchers have long known that women who have children, especially those who have them at an early age and have full-term pregnancies, have a reduced risk of breast cancer overall. Although never giving birth appears to have a protective effect against triple-negative breast cancer, it increases the risk of the more common estrogen-receptor-positive breast cancer. Dr. Phipps’ results underscore the fact that breast cancer is really a complex collection of many different diseases, all of which must be better understood to improve care.
Scientists don’t yet know how full-term pregnancy may contribute to an increased risk of triple-negative breast cancer and a decreased risk of other forms of the disease, but several possible mechanisms are being investigated, including the effects that pregnancy-related hormones may have on breast cells. By shedding light on the risk factors for specific subtypes of breast cancer, Dr. Phipps’ studies promise to help scientists develop better tools to identify those women at greatest risk as well as improved early detection and treatment strategies.
Thank you
We are grateful for your support of the Climb to Fight Breast Cancer. Your generous contributions through the Climb help sustain our scientists in their unwavering commitment to improve the lives of women with, and at risk, for the disease.
There are many opportunities for joining studies at the Center. For details, visit: www.fhcrc.org/other/study.
Like this:
Be the first to like this post.